Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Novel Lung Cancer Therapy: Future Improvements and Challenges

MET as a Clinical Target in Lung Cancer

Expanding the NSCLC Armamentarium: IMpower131

Extensive-Stage SCLC: Potential in the CASPIAN Trial

Targeted Therapy for KRAS p.G12C NSCLC

Future Directions in Lung Cancer Management

Metastatic NSCLC: Interpreting Data From NEPTUNE

Updated Data in Stage IV NSCLC: CheckMate-227

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

Advanced-Stage NSCLC: Overall Survival Data From FLAURA

Overview of Novel Therapy for Advanced-Stage NSCLC

Key Takeaway 6: Role of Immunotherapy in R/R mHCC

Key Takeaway 5: High AFP is a Biomarker for Ramucirumab

Key Takeaway 4: Second-Line Regorafenib After TKI in HCC

Key Takeaway 3: Role of Frontline I/O Still Pending

Key Takeaway 2: Initial Systemic Therapy in HCC

Key Takeaway 1: Multidisciplinary Management of HCC

The FDA has approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score ≥10) as determined by an FDA-approved test, with disease progression after ≥1 prior lines of systemic therapy.

FDA Approves Pembrolizumab for PD-L1+ Esophageal Cancer

In the phase III PROSPER trial, investigators will attempt a novel approach in localized renal cell carcinoma: priming the immune system prior to nephrectomy with neoadjuvant nivolumab and continuing with adjuvant blockade. The study will be the first to combine neoadjuvant and adjuvant immunotherapy with standard of care nephrectomy.

Investigators Seek to Boost Surgical Cures in RCC With Immune Priming

Drug Development and Final Thoughts

Immuno-Oncology

Immuno-Oncology | Specialty